Personalized dosimetry assessment of [ 177 Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer.

Mahmood Kazemi-JahromiElmira Yazdani Najme Karamzade-ZiaratiMahboobeh AsadiMahdi Sadeghi Parham Geramifar

Published in: International journal of radiation biology (2024)

Lu]Lu-PSMA-617 RLT is feasible and does not pose a significant risk of adverse effects on OARs, as supported by our data. However, to validate the safety and efficacy of higher doses, further clinical follow-up studies are recommended.

Keyphrases

pet ct
pet imaging
small cell lung cancer
squamous cell carcinoma
electronic health record
emergency department
stem cells
computed tomography
big data
machine learning
mesenchymal stem cells
case control
cell therapy